Compare TARA & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | FLC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.6M | 162.4M |
| IPO Year | 2014 | 2003 |
| Metric | TARA | FLC |
|---|---|---|
| Price | $2.30 | $15.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $25.33 | N/A |
| AVG Volume (30 Days) | ★ 852.9K | 23.2K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $15.33 |
| 52 Week High | $7.82 | $18.09 |
| Indicator | TARA | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 45.66 |
| Support Level | $2.19 | $15.40 |
| Resistance Level | $2.73 | $15.85 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 34.43 | 22.98 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.